Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 344Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Early access programs: Benefits, challenges, and key considerations for successful implementation

Patil Sanjaykumar

Year : 2016| Volume: 7| Issue : 1 | Page no: 4-8

   This article has been cited by
 
1 To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
Peter Martin,Andre Goy,Radhakrishnan Ramchandren,Lucille Ferrante,Anil Londhe,Tracy McGowan,Nancy L Bartlett
Journal of Oncology Pharmacy Practice. 2019; 25(4): 1027
[Pubmed]  [Google Scholar] [DOI]
2 Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 Patterns of Alternative Access: unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice
Beatrice Borelli,Gemma Zucchelli,Daniele Rossini,Chiara Cremolini,Carlotta Antoniotti,Roberto Moretto,Federica Marmorino,Camilla Colombo,Francesca Vannini,Laura Delliponti,Mario Spione,Elena Ongaro,Gianluca Masi,Isa Maura Brunetti,Elisabetta Pfanner,Lisa Salvatore,Alfredo Falcone
Colorectal Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing
Aaron S. Mansfield,Ben Ho Park,Michael P. Mullane
American Society of Clinical Oncology Educational Book. 2018; (38): 873
[Pubmed]  [Google Scholar] [DOI]
6 Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari,Sagar Lonial,Tomer M. Mark,Amrita Y. Krishnan,Keith E. Stockerl-Goldstein,Saad Z. Usmani,Anil Londhe,Delores Etheredge,Sarah Fleming,Baolian Liu,Jon Ukropec,Thomas S. Lin,Sundar Jagannath,Ajay K. Nooka
Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
7 Physician perspectives on compassionate use in pediatric oncology
Scott Moerdler,Lindy Zhang,Elena Gerasimov,Chong Zhu,Tamar Wolinsky,Michael Roth,Nancy Goodman,Daniel A. Weiser
Pediatric Blood & Cancer. 2018; : e27545
[Pubmed]  [Google Scholar] [DOI]
8 Expanding Patient Access to Investigational New Drugs
Gail A. Van Norman
JACC: Basic to Translational Science. 2018; 3(3): 403
[Pubmed]  [Google Scholar] [DOI]
9 An overview of Compassionate Use Programs in the European Union member states
Gayathri Balasubramanian,Suman Morampudi,Pankdeep Chhabra,Arun Gowda,Behsad Zomorodi
Intractable & Rare Diseases Research. 2016; 5(4): 244
[Pubmed]  [Google Scholar] [DOI]

 

Read this article